| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514253060 | Quinolines (including hydrogenated) | 41 |
| 20080221120 | Modulation of Aquaporin in Modulation of Angiogenesis and Cell Migration - The invention provides compositions, pharmaceutical preparations, and methods for modulating angiogenesis and/or cell migration in a subject having a cellular proliferative disease (e.g., cancer), or a disease or condition amenable to treatment by enhancing cellular proliferation and cell migration (e.g., angiogenesis), by modulating the activity of an aquaporin, such as aquaporin-1. The compositions and pharmaceutical preparations of the invention may comprise one or more of compounds that modulate the activity of aquaporin-1. | 09-11-2008 |
| 20080275057 | Compounds with anti-cancer activity - Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents. | 11-06-2008 |
| 20080293737 | ION CHANNEL MODULATORS AND METHODS OF USE - In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels. | 11-27-2008 |
| 20080300258 | ANHYDROUS CIPROFLOXACIN HYDROCHLORIDE - The present invention provides a new anhydrous crystalline form of ciprofloxacin hydrochloride that is substantially free from solvent molecules, and processes of preparation thereof. | 12-04-2008 |
| 20090030013 | SUBSTITUTED TETRAHYDRO-QUINOLINE-SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS - The present invention refers to substituted tetrahydro-quinoline-sulfonamide compounds of general formula (I): | 01-29-2009 |
| 20090054454 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE - Benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such compounds are disclosed. Methods of using benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such composition in the treatment and/or prevention of serotonin-related disorders, such as depression and anxiety, are also disclosed. In addition, processes for the preparation of benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives are disclosed. | 02-26-2009 |
| 20090069338 | Method for predicting skin sensitizing activity of compounds - Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed. | 03-12-2009 |
| 20090088441 | Quinoline Compounds - The present invention relates to novel compounds of the general formula (I) | 04-02-2009 |
| 20090291963 | SUBSTITUTED INDOLES - Substituted indoles of the formula (I) and physiologically acceptable derivatives and salts thereof, in which R | 11-26-2009 |
| 20100004261 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE - Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis). | 01-07-2010 |
| 20100087445 | ARYL PIPERAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS - This invention provides novel aryl piperazine derivatives represented by Formula (I) having medical utility, in particular as modulators of dopamine and serotonin receptors, preferably the D | 04-08-2010 |
| 20100113473 | ARYL AMIDE COMPOUND AS AN ACETYL COENZYME A CARBOXYLASE INHIBITOR - An aryl amide compound of Formula (I): | 05-06-2010 |
| 20100144751 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS - Compounds of Formula (I): are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class (3) and class (5) receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1. | 06-10-2010 |
| 20100286164 | SUBSTITUTED ARYL ALKYLAMINO-OXY-ANALOGS AND USES THEREOF - Aspects of the invention relate to substituted aryl propylamino-oxy-analogs and uses thereof. Aspects of the invention relate to compositions that are inhibitors of γ-secretase and uses thereof for treating subjects having, or at risk of developing, Alzheimer's disease. | 11-11-2010 |
| 20100324066 | CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERA- ZINYL)PROPOXY]-3-QUINOLINECARBONITRILE AND METHODS OF PREPARING THE SAME - This invention is directed to a crystalline 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile monohydrate having an x-ray diffraction pattern wherein 2θ angles (°) of significant peaks are at about: 9.19, 11.48, 14.32, 19.16, 19.45, 20.46, 21.29, 22.33, 23.96, 24.95, 25.29, 25.84, 26.55, 27.61, and 29.51, and a transition temperature of about 109° C. to about 115° C. | 12-23-2010 |
| 20110009419 | Enantiomers of 2'-Fluoralkyl-6-nitroquipazine as Serotonin Transporter Positron Emission Tomography Imaging Agents and Antidepressant Therapeutics - Racemic mixtures and individual enantiomers of fluorine-18 or carbon-11 radiolabelled 2′-alkyl-6-nitroquipazine ligands are serotonin transporter (SERT) tracers for positron emission tomography (PET) imaging. The non-radioactive ligand forms possess therapeutic antidepressant in vitro and in vivo pharmacological binding profiles in rodent brain and cells expressing human serotonin transporter (hSERT). Twelve 2′-alkyl-6-nitroquipazine ligands potently bind in sub-nanomolar concentrations to the pre-synaptic SERT binding site where established antidepressant drugs bind and inhibit the re-uptake of the neurotransmitter serotonin (5-HT). In vivo tracer studies in rats as well as monkey PET scan trial have demonstrated the fluorine-18 and carbon-11 positron radionuclide labeled tracers perform as quantitative tracers of specific binding the SERT protein in live brain. | 01-13-2011 |
| 20110092514 | COMPOUNDS WITH ANTI-CANCER ACTIVITY - Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents. | 04-21-2011 |
| 20110092515 | MELT GRANULATION PROCESS - A process for preparing solid dosage forms that contain a quinoline compound. The process, for example, provides for the inventive use of an extruder, especially a twin screw extruder, to melt granulate the quinoline compound with a granulation excipient. | 04-21-2011 |
| 20110190315 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD - The subject invention concerns methods and compounds for inhibiting Shp2. In one embodiment, a compound of the invention has a chemical structure as shown in formula I or II: | 08-04-2011 |
| 20120149712 | Methods for improving kidney function - The invention relates to methods for improving renal (kidney) function. Methods for decreasing blood urea nitrogen (BUN), for increasing glomerular filtration rate (GFR), and for decreasing serum creatinine are also provided. | 06-14-2012 |
| 20120149713 | ORAL FILMS COMPRISING 7-[4-[4-(2,3-DICHLOROPHENYL) PIPERAZIN-1-L]BUTOXY]-3,4-DIHYDRO-1H-QUINOLIN-2-ONE BASE OR SALTS OR HYDRATES THEREOF - An oral film comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one base or salts or hydrates thereof. | 06-14-2012 |
| 20120302581 | Methods and Compositions for the Treatment of RAS Associated Disorders - The instant disclosure relates to compositions that may be useful as therapeutic agents for the treatment of disorders associated or caused by Ras deregulation or dysregulation, for example, disorders associated with alterations in the NF1 gene such as neurofibromatosis type I, fungal infections such as those caused by | 11-29-2012 |
| 20130053396 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS - The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smo antagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example basal cell carcinoma, medulloblastoma, prostate, pancreatic, breast, colon, bone and small cell lung cancers, and cancers of the upper GI tract. | 02-28-2013 |
| 20130172363 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS - Benzenesulfonamide compounds having a structure of formula (I) are described. Also described, are methods for synthesizing the compounds and to the use thereof in pharmaceutical compositions for human or veterinary medicine and in cosmetic compositions. | 07-04-2013 |
| 20130324552 | CHEMOKINE CXCR4 RECEPTOR MODULATORS AND USED RELATED THERETO - The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing CXCR4 related conditions, typically prevention or treatment of viral infections such as HIV or for managing cancer. | 12-05-2013 |
| 20130338170 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF - The invention relates to compounds of formula IA | 12-19-2013 |
| 20140107129 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS - Benzenesulfonamide compounds having a structure of formula (I) are described. Also described, are methods for synthesizing the compounds and to the use thereof in pharmaceutical compositions for human or veterinary medicine and in cosmetic compositions. | 04-17-2014 |
| 20140142114 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF - The present invention relates to novel anthelmintic compounds of formula (I) below: | 05-22-2014 |
| 20140194439 | METHODS OF TARGETED DRUG DEVELOPMENT - Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR. | 07-10-2014 |
| 20140221387 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES - The present invention relates to a compositions for and methods of cancer treatment in which compounds of Formula I or Formula II. In some aspects, the treatment of B-cell Lymphoma or other hematopoietic cancers is encompassed. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds of Formula I or Formula II. Combination therapy with, for example, a class of therapeutics known as 26S proteasome inhibitors, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formula I or Formula II. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease. | 08-07-2014 |
| 20140275108 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS - Provided herein are novel benzenesulfonamide compounds having a structure of formula (I) below: | 09-18-2014 |
| 20140296251 | MULTIFUNCTIONAL QUINOLINE DERIVATIVES AS ANTI-NEURODEGENERATIVE AGENTS - Novel quinoline derivatives are disclosed. Also disclosed are synthesis and use thereof for treating neurodegenerative diseases. | 10-02-2014 |
| 20150018366 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF - The invention relates to compounds of formula IA | 01-15-2015 |
| 20150025085 | Iron Chelators And Uses Thereof - 8-Hydroxy-quinoline derivatives and 8-ethers, 8-esters, 8-carbonates, 8-acyloxymethyl, 8-phosphates, 8(phosphoryloxy)methyl, and 8-carbamates derivatives thereof substituted at the 5-position are described as useful for iron chelation and neuroprotective therapies. | 01-22-2015 |
| 20150087653 | TREATING NEURAL DISEASE WITH TYROSINE KINASE INHIBITORS - Provided herein are methods of treating or preventing a neurodegenerative disease, a myodegenerative disease or a prion disease in a subject comprising administering a tyrosine kinase inhibitor. | 03-26-2015 |
| 20150133466 | SENSITIZATION OF CANCER CELLS TO DNA DAMAGE BY INHIBITING KINASES ESSENTIAL FOR DNA DAMAGE CHECKPOINT CONTROL - The invention provides methods for overriding cell cycle arrest in a tumor cell, which comprise inducing DNA damage in the cell, and contacting the cell with an amount of bosutinib or a bosutinib isomer effective to inhibit one or more kinase constituents of a DNA damage checkpoint pathway. The invention also provides novel bosutinib isomers, as well as compositions of the novel isomers and the bosutinib isomer 3,5-dichloro-4-methoxyaniline. | 05-14-2015 |
| 20150352097 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES - The present invention relates to a compositions for and methods of cancer treatment in which compounds of Formula I or Formula II. In some aspects, the treatment of B-cell Lymphoma or other hematopoietic cancers is encompassed. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds of Formula I or Formula II. Combination therapy with, for example, a class of therapeutics known as 26S proteasome inhibitors, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formula I or Formula II. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease. | 12-10-2015 |
| 20160009697 | PYRIDINE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS | 01-14-2016 |
| 20160185726 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF - The present invention relates to novel anthelmintic compounds of formula (I) below: | 06-30-2016 |
| 20190142819 | TREATMENT OF RENAL CELL CARCINOMA WITH LENVATINIB AND EVEROLIMUS | 05-16-2019 |
| 20190144417 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | 05-16-2019 |
